BeStock  
Stocks › Biotechnology › DSGN

Design Therapeutics DSGN

US equityMarket cap rank #3510Biotechnology
$9.02 −$0.30 (-3.22%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.02 0.00%
Open$9.33
Prev close$9.32
Day range$8.96 – $9.57
Volume281.9K
Market cap$577.61M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$22.23M-15.1% YoY
Net profit-$20.29M-19.4% YoY
Diluted EPS-$0.32-6.7% YoY
Free cash flow-$15.39M-37.9% YoY
Operating cash flow-$15.38M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-13.7MDec '24$-17.7MMar '25$-19.1MJun '25$-17.0MSep '25$-16.0MDec '25$-17.6MMar '26$-20.2MJun '26$-20.3MSep '26

Diluted EPS by quarter

-0.24Dec '24-0.31Mar '25-0.34Jun '25-0.30Sep '25-0.27Dec '25-0.29Mar '26-0.32Jun '26-0.32Sep '26

Free cash flow by quarter

$-9.9MDec '24$-16.9MMar '25$-14.5MJun '25$-11.2MSep '25$-12.0MDec '25$-16.4MMar '26$-15.5MJun '26$-15.4MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-36.9%
Return on assets-34.6%
Return on invested capital-40.5%
Current ratio16.78
Liabilities / assets6.7%
Cash & investments$208.61M
Total debt$1.86M
Net cash (debt)$206.75M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $22.23M $22.18M $19.71M $79.47M $18.17M
Selling and Admin Expenses $5.30M $5.79M $5.33M $20.34M $4.74M
-General & Admin Expense $5.30M $5.79M $5.33M $20.34M $4.74M
Research & Development $16.93M $16.39M $14.38M $59.13M $13.43M
Operating Profit -$22.23M -$22.18M -$19.71M -$79.47M -$18.17M
Net Non-Operating Interest Income (Expense) $1.94M $2.01M $2.07M $9.68M $2.17M
Non-Operating Interest Income $1.94M $2.01M $2.07M $9.68M $2.17M
Pretax Profit -$20.29M -$20.17M -$17.64M -$69.79M -$16.00M
Net Profit -$20.29M -$20.17M -$17.64M -$69.79M -$16.00M
Profit from Continuing Operations -$20.29M -$20.17M -$17.64M -$69.79M -$16.00M
Net Income to Parent Company -$20.29M -$20.17M -$17.64M -$69.79M -$16.00M
Net Income to Common Stockholders -$20.29M -$20.17M -$17.64M -$69.79M -$16.00M
Basic EPS -$0.32 -$0.32 -$0.29 -$1.22 -$0.27
Diluted EPS -$0.32 -$0.32 -$0.29 -$1.22 -$0.27

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $216.81M $215.13M $230.44M $226.20M $226.20M
Total Current Assets $213.96M $212.01M $227.05M $223.78M $223.78M
Cash and Cash Equivalents & Short-Term Investments $208.61M $207.40M $222.82M $219.85M $219.85M
-Cash and Cash Equivalents $15.25M $12.91M $12.77M $16.86M $16.86M
-Short Term Investments $193.36M $194.49M $210.05M $202.99M $202.99M
Receivables $1.74M $1.79M $1.82M $1.68M $1.68M
-Accrued Interest Receivable $1.74M $1.79M $1.82M $1.68M $1.68M
Prepaid Assets $3.61M $2.83M $2.40M $2.26M $2.26M
Total Non-Current Assets $2.85M $3.12M $3.39M $2.42M $2.42M
Net PPE $2.85M $3.12M $3.39M $2.42M $2.42M
-Gross PPE $5.55M $5.69M $5.81M $4.68M $4.68M
-Accumulated Depreciation -$2.71M -$2.57M -$2.42M -$2.26M -$2.26M
Total Liabilities $14.61M $13.27M $12.39M $13.70M $13.70M
Total Current Liabilities $12.75M $11.24M $10.19M $13.06M $13.06M
Payables $2.08M $3.14M $2.28M $2.31M $2.31M
-Accounts Payable $2.08M $3.14M $2.28M $2.31M $2.31M
Current Accrued Expenses $6.09M $4.68M $5.05M $5.22M $5.22M
Short-Term Debt and Capital Lease Obligation $655,000.00 $631,000.00 $536,000.00 $890,000.00 $890,000.00
-Current Capital Lease Obligation $655,000.00 $631,000.00 $536,000.00 $890,000.00 $890,000.00
Total Non-Current Liabilities $1.86M $2.03M $2.20M $645,000.00 $645,000.00
Long Term Debt and Capital Lease Obligation $1.86M $2.03M $2.20M $645,000.00 $645,000.00
-Long Term Capital Lease Obligation $1.86M $2.03M $2.20M $645,000.00 $645,000.00
Total Equity $202.20M $201.86M $218.05M $212.50M $212.50M
Stockholders' Equity $202.20M $201.86M $218.05M $212.50M $212.50M
Capital Stock $6,000.00 $6,000.00 $6,000.00 $6,000.00 $6,000.00
-Common Stock $6,000.00 $6,000.00 $6,000.00 $6,000.00 $6,000.00
Additional Paid-In Capital $558.97M $537.43M $532.96M $509.10M $509.10M
Retained Earnings -$355.10M -$334.81M -$314.64M -$297.01M -$297.01M
Gains/Losses Not Affecting Retained Earnings -$1.68M -$771,000.00 -$268,000.00 $403,000.00 $403,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$15.38M -$15.52M -$16.43M -$54.36M -$11.97M
Net cash flow from continuing operations -$15.38M -$15.52M -$16.43M -$54.36M -$11.97M
Net Income from Continuing Operations -$20.29M -$20.17M -$17.64M -$69.79M -$16.00M
Depreciation & Depletion & Amortization $136,000.00 $151,000.00 $157,000.00 $622,000.00 $156,000.00
Other Non-Cash Items $2,000.00 $74,000.00 $69,000.00 $406,000.00 -$8,000.00
Change in Working Capital $703,000.00 $564,000.00 -$2.80M $3.11M $960,000.00
-Change in Prepaid Assets -$738,000.00 -$391,000.00 -$287,000.00 -$1.38M -$880,000.00
-Change in Payables and Accrued Expense $1.44M $955,000.00 -$2.51M $4.49M $1.84M
Net cash flow from investing $189,000.00 $15.06M -$7.59M $22.91M -$11.58M
Net Cash Flow from Continuing Investing Activities $189,000.00 $15.06M -$7.59M $22.91M -$11.58M
Net PPE Purchase and Sale -$15,000.00 -$21,000.00 $0.00 -$193,000.00 -$34,000.00
Net Investment Purchase and Sale $204,000.00 $15.08M -$7.59M $23.11M -$11.55M
Financing Cash Flow $17.53M $605,000.00 $19.93M $25.74M $25.32M
Net Cash Flow from Continuing Financing Activities $17.53M $605,000.00 $19.93M $25.74M $25.32M
Net Common Stock Issuance $17.26M $0.00 $19.91M $24.85M $24.85M
Proceeds from Stock Option Exercised $277,000.00 $605,000.00 $27,000.00 $891,000.00 $470,000.00
Ending Cash Balance $15.25M $12.91M $12.77M $16.86M $16.86M
Net Change in Cash $2.35M $137,000.00 -$4.09M -$5.71M $1.77M
Beginning Cash Balance $12.91M $12.77M $16.86M $22.56M $15.09M
Free Cash Flow -$15.39M -$15.55M -$16.43M -$54.55M -$12.00M

Discussion

No comments yet — be the first to weigh in on DSGN.

Sign in to join the discussion.

Scroll to Top